Publicacións en colaboración con investigadores/as de Hospital de Manises (19)

2023

  1. Spanish cardiac catheterization and coronary intervention registry. 32nd official report of the Interventional Cardiology Association of the Spanish Society of Cardiology (1990-2022)

    Revista Espanola de Cardiologia, Vol. 76, Núm. 12, pp. 1021-1031

  2. Ustekinumab and vedolizumab for the prevention of postoperative recurrence of Crohn's disease: Results from the ENEIDA registry

    Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver, Vol. 55, Núm. 1, pp. 46-52

2022

  1. Risk Factors for COVID-19 in Inflammatory Bowel Disease: A National, ENEIDA-Based Case–Control Study (COVID-19-EII)

    Journal of Clinical Medicine, Vol. 11, Núm. 24

  2. Using Interpretable Machine Learning to Identify Baseline Predictive Factors of Remission and Drug Durability in Crohn’s Disease Patients on Ustekinumab

    Journal of Clinical Medicine, Vol. 11, Núm. 15

2021

  1. Renin-angiotensin system inhibitors effect before and during hospitalization in COVID-19 outcomes: Final analysis of the international HOPE COVID-19 (Health Outcome Predictive Evaluation for COVID-19) registry

    American Heart Journal, Vol. 237, pp. 104-115

2020

  1. Impact of COVID-19 on ST-segment elevation myocardial infarction care. The Spanish experience

    Revista Espanola de Cardiologia, Vol. 73, Núm. 12, pp. 994-1002

2019

  1. IHDIP: A controlled randomized trial to assess the security and effectiveness of the incremental hemodialysis in incident patients

    BMC Nephrology, Vol. 20, Núm. 1

  2. Multicentric study on total pancreatectomies

    Cirugia Espanola, Vol. 97, Núm. 7, pp. 377-384

2018

  1. Addition of granulocyte/monocyte apheresis to oral prednisone for steroid-dependent ulcerative colitis: A Randomized multicentre clinical trial

    Journal of Crohn's and Colitis, Vol. 12, Núm. 6, pp. 687-694

2017

  1. Characterization of Surgical Procedures in the Spanish Mohs Surgery Registry (REGESMOHS) for 2013-2015

    Actas Dermo-Sifiliograficas, Vol. 108, Núm. 9, pp. 836-843

  2. Down syndrome as risk factor for respiratory syncytial virus hospitalization: A prospective multicenter epidemiological study

    Influenza and other Respiratory Viruses, Vol. 11, Núm. 2, pp. 157-164

  3. Efficacy and safety of eslicarbazepine-acetate in elderly patients with focal epilepsy: Case series

    Seizure, Vol. 48, pp. 53-56

  4. Evolution after Anti-TNF Discontinuation in Patients with Inflammatory Bowel Disease: A Multicenter Long-Term Follow-Up Study

    American Journal of Gastroenterology, Vol. 112, Núm. 1, pp. 120-131

2016

  1. Standardization of the homogeneous mobility shift assay protocol for evaluation of anti-infliximab antibodies. Application of the method to Crohn's disease patients treated with infliximab

    Biochemical Pharmacology, Vol. 122, pp. 33-41

  2. Tuberculosis in anti-tumour necrosis factortreated inflammatory bowel disease patients after the implementation of preventive measures: Compliance with recommendations and safety of retreatment

    Journal of Crohn's and Colitis, Vol. 10, Núm. 10

2015

  1. Description of Patients Undergoing Mohs Surgery in Spain: Initial Report on Data from the Spanish Registry of Mohs Surgery (REGESMOHS)

    Actas Dermo-Sifiliograficas, Vol. 106, Núm. 7, pp. 562-568

2014

  1. Long-term safety and efficacy of eslicarbazepine acetate in patients with focal seizures: Results of the 1-year ESLIBASE retrospective study

    Epilepsy Research, Vol. 108, Núm. 7, pp. 1243-1252

2012

  1. Efficacy of infliximab rescue therapy in patients with chronic refractory pouchitis: A multicenter study

    Inflammatory Bowel Diseases, Vol. 18, Núm. 5, pp. 812-817

  2. Incidence, characteristics and risk factors of marked hyperbilirubinemia after allogeneic hematopoietic cell transplantation with reduced-intensity conditioning

    Bone Marrow Transplantation, Vol. 47, Núm. 10, pp. 1343-1349